Adam Nelson MBBS MBA/MPH PhD FRACP is an early career interventional cardiologist and clinical triallist appointed at the Royal Adelaide and Queen Elizabeth Hospitals, and clinical academic at the University of Adelaide. He is a clinical lead of national and international trials evaluating emerging cardiometabolic therapies and has an interest in implementation science.

Dr. Michael Miller is a cardiologist, Professor and Vice Chair of Medicine at the Hospital of the University of Pennsylvania. He has had a longstanding interest in triglyceride metabolism, chaired the AHA scientific statement, “Triglycerides and Cardiovascular Disease (CVD)” and co-authored AHA/ACC statements on Dietary Fats and CVD, Omega-3 Fatty Acids for hypertriglyceridemia (HTG) and the Expert Consensus Decision Pathway on Cardiovascular Risk Reduction in HTG.

Dr. R. Preston Mason has been a member of the Cardiovascular Division at Brigham and Women’s Hospital and Harvard Medical School in Boston, Massachusetts, USA. Dr Mason is President and Founder of Elucida Research, a biotechnology research firm in Beverly, Massachusetts. He has received many awards for his research in cardiovascular pharmacology and teaching over the past 35 years. Prior to coming to Boston, he was on the faculties of the University of Connecticut School of Medicine and Drexel University School of Medicine as professor. Dr. Mason has served on a number of grant review committees for the National Institute of Health, American Heart Association and reviewer for a number of prestigious journals. He has authored or co-authored 200 full scientific articles, has multiple patents and receives frequent requests to speak at national and international conferences. He has published over 50 research articles and given more than 100 scientific presentations related specifically to his research on the role of omega-3 fatty acids in cardiovascular disease

Gemma is a Professor in Medicine at the University of Sydney and an Interventional Cardiologist at Royal North Shore Hospital in Sydney. She is the Chair of the University of Sydney’s multi-disciplinary Cardiovascular Initiative. Gemma is committed to improving the care for heart attack patients, unravelling key mechanisms underlying susceptibility and response to heart attack, with studies extending from the bench to large cohort studies and clinical trials. Discoveries in her Laboratory have been published in leading journals including the Lancet, Circulation, JACC and European Heart Journal, with > 250 publications. Gemma is a principal investigator on grants >$26 Mill. Her discoveries and innovative strategies have resulted in a US patent, and 5 provisional patents spanning diagnostic and therapeutic fields. Gemma is founder and CSO for Australian start-ups Prokardia and Kardiomics, and the not-for-profit CAD Frontiers Pty Ltd. She was awarded a National Health and Medical Research Council (NHMRC) Excellence Award for Top Ranked Practitioner Fellow (Australia- 2018), NSW Ministerial Award for Cardiovascular Research Excellence (2019) and was the second female to be awarded the prestigious Cardiac Society of Australia and New Zealand RT Hall Prize for outstanding and sustained research achievement (2023). Gemma serves as a member of the Editorial Board of leading international journals including Circulation and Cardiovascular Research and an Associate Editor for Heart, Lung and Circulation. She is a passionate advocate for cardiovascular research, working as President of the Australian Cardiovascular Alliance with a national team to secure $220 Million Federal funding for the Mission for Cardiovascular Health, and to build new pathways for research to best serve the unmet health needs of Australians. She chairs the MRFF Mission (CV) Expert Advisory Panel. She is a graduate of the Australian Institute of Company Directors and serves/has served as a non-executive Director on multiple community Boards, including the Heart Foundation. In 2023, Gemma was appointed a Member of the Order of Australia (AM), in the Australia Day Honours.